Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review‐based cohort study

Abstract

Ensuring representative data accrual in clinical trials is important to safeguard the generalizability of results and to minimize disparities in care. This study s goal was to evaluate differences in gender representation in trials leading to US Food and Drug Administration (FDA) cancer drug approvals.